The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT);
Vale, Claire L;
Godolphin, Peter J;
Fisher, David J;
Higgins, Julian PT;
Mcaleenan, Alexandra;
Spiga, Francesca;
... Murthy, Srinivas; + view all
(2024)
Anticoagulation Among Patients Hospitalized for COVID-19: A Systematic Review and Prospective Meta-analysis.
Annals of Internal Medicine
10.7326/ANNALS-24-00800.
(In press).
![[thumbnail of Godolphin_10-25 submitted ANNALS.pdf]](https://discovery-pp.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Godolphin_10-25 submitted ANNALS.pdf - Accepted Version Access restricted to UCL open access staff until 25 June 2025. Download (2MB) |
|
Text
Godolphin_ANNALS-24-00800R3_3_Appendix_Material.pdf - Accepted Version Access restricted to UCL open access staff until 25 June 2025. Download (3MB) |
Abstract
Background: Reported results of clinical trials assessing higher-dose anticoagulation in patients hospitalized for COVID-19 have been inconsistent. // Purpose: To estimate the association of higher- versus lower-dose anticoagulation with clinical outcomes. // Data Sources: Randomized trials were identified from the World Health Organization's International Clinical Trials Registry Platform and ClinicalTrials.gov with no restriction by trial status or language. // Study Selection: Eligible randomized trials assigned patients hospitalized for COVID-19 to higher- versus lower-dose anticoagulation. // Data Extraction: 20 eligible trials provided data in a prospectively agreed format. Two further studies were included based on published data. The primary outcome was all-cause mortality 28 days after randomization. Secondary outcomes were progression to invasive mechanical ventilation or death, thromboembolic events, and major bleeding. // Data Synthesis: Therapeutic- compared with prophylactic-dose anticoagulation with heparins reduced 28-day mortality (OR, 0.77 [95% CI, 0.64 to 0.93]; I 2 = 29%; 11 trials, 6297 patients, of whom 5456 required low or no oxygen at randomization). The ORs for 28-day mortality were 1.21 (CI, 0.93 to 1.58; I 2 = 0%) for therapeutic-dose compared with intermediate-dose anticoagulation (6 trials, 1803 patients, 843 receiving noninvasive ventilation at randomization) and 0.95 (CI, 0.76 to 1.19; I 2 = 0%; 10 trials, 3897 patients, 2935 receiving no or low oxygen at randomization) for intermediate- versus prophylactic-dose anticoagulation. Treatment effects appeared broadly consistent across predefined patient subgroups, although some analyses were limited in power. Higher- compared with lower-dose anticoagulation was associated with fewer thromboembolic events, but a greater risk for major bleeding. // Conclusion: Therapeutic-dose compared with prophylactic-dose anticoagulation reduced 28-day mortality. Mortality was similar for intermediate-dose compared with prophylactic-dose anticoagulation and higher for therapeutic-dose compared with intermediate-dose anticoagulation, although this comparison was not estimated precisely. // Primary Funding Source: No direct funding. (PROSPERO: CRD42020213461)
| Type: | Article |
|---|---|
| Title: | Anticoagulation Among Patients Hospitalized for COVID-19: A Systematic Review and Prospective Meta-analysis |
| Location: | United States |
| DOI: | 10.7326/ANNALS-24-00800 |
| Publisher version: | https://doi.org/10.7326/annals-24-00800 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Anticoagulants; Cardiology and cardiovascular diseases; Clinical trials; COVID-19; Hemorrhage; Hospital medicine; Mortality; Prophylaxis; Randomized trials; Vascular medicine |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10203459 |
Archive Staff Only
 |
View Item |
